Video

Dr. Smith Advises Clinicians on Diagnosing Double-Hit and Triplet-Hit Lymphoma

Sonali M. Smith, MD, Elwood V. Jensen Professor in Medicine, director, Lymphoma Program, University of Chicago Medicine, advises clinicians on diagnosing double-hit and triple-hit lymphoma in patients with diffuse large B-cell lymphoma.

Sonali M. Smith, MD, Elwood V. Jensen Professor in Medicine, director, Lymphoma Program, University of Chicago Medicine, advises clinicians on diagnosing double-hit and triple-hit lymphoma in patients with diffuse large B-cell lymphoma (DLBCL).

Double-hit and triplet-hit lymphomas are uncommon but not rare, and needs to be looked for in patients diagnosed with DLBCL, Smith says. This subtype is enriched in patients with a germinal center phenotype, as well in those with high-risk features. Smith says that the most important thing is to take a big enough biopsy. If there is a suspicion for an aggressive B-cell lymphoma, Smith advises clinicians to take enough tissue to test for it during initial biopsy.

The most important thing to do when a patient presents with a double-hit lymphoma is to confirm the diagnosis with the pathologist, Smith says. Nuances including amplification, copy number alterations, and mutations can make a difference. Additionally, Smith says that R-CHOP is not going to be sufficient, and clinicians should consider a more intensive therapeutic regimen for these patients.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Related Videos
R. Lor Randall, MD, FACS
Joshua Richter, MD of Tisch Cancer Institute
Guenther Koehne, MD, deputy director and chief of Stem Cell Transplantation, Hematologic Oncology and Benign Hematology at Miami Cancer Institute, Baptist Health South Florida
Grzegorz S. Nowakowsi, MD, a consultant in the Division of Hematology in the Department of Internal Medicine and the Enterprise Deputy Director of Clinical Research at the Mayo Clinic Comprehensive Cancer Center
Bradley McGregor, MD
Katherine L. Nathanson, MD
Daniel J. DeAngelo, MD, PhD, chief of the Division of Leukemia and an institute physician at Dana-Farber Cancer Institute, as well as a professor of medicine at Harvard Medical School
Julie M. Vose, MD, MBA
6369343864112
Matthew Wagar, MD of the University of Wisconsin School of Medicine and Public Health